• Previous studies suggest that immune-mediated platelet clearance following transfusion represents an antibody-mediated process.
Introduction
Although over 1.5 million platelet transfusions occur each year, 1 a significant portion of individuals who receive platelets fail to achieve the desired therapeutic benefit due to accelerated platelet clearance. 2, 3 While clearance can occur through nonimmune-related mechanisms, 4 many studies demonstrate the importance of immune-mediated clearance. 2, 3, [5] [6] [7] [8] Historically, immune-mediated platelet clearance, termed refractoriness, was attributed solely to anti-platelet alloantibodies predominately targeted to major histocompatibility complex (MHC) antigens. 5, 7 In the absence of detectable anti-platelet alloantibodies, platelet clearance is invariably considered nonimmune in nature. 5, 6 However, although studies demonstrate that some individuals can fail platelet therapy in the complete absence of detectable antiplatelet alloantibodies, 2, 3 nonimmune mechanisms often fail to fully explain platelet clearance, suggesting that immune-mediated platelet clearance may occur independent of anti-platelet alloantibodies. 
Study design

Assessing antibody-independent platelet refractoriness
To evaluate antibody-independent platelet clearance, mMT mice (B-cell-deficient C57BL/6, H-2 b ) were immunized and transfused with B6 GFP or FVB GFP platelets, followed by evaluation of platelet clearance, as outlined in the previous paragraph. Absence of antibody was confirmed by western blot analysis of serum from naive and immunized C57BL/6 and mMT mice. Specific immune cell subsets were eliminated from immunized mMT mice prior to platelet transfusion by injection of monoclonal CD8-depleting antibody (clone 2.43) or NK1.1 monoclonal antibody (clone PK-136), respectively. Depletions were confirmed by flow cytometry.
Please refer to supplemental Materials (available on the Blood Web site) for detailed methodology.
Results and discussion
Although previous studies provide insight into the development of anti-platelet alloantibodies, 2,9-14 few models exist to evaluate The online version of this article contains a data supplement.
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mechanisms of platelet refractoriness in transfused recipients. Therefore, we first developed a model to evaluate mechanisms whereby platelet clearance may occur following MHC alloimmunization. To accomplish this, C57BL/6 (H-2 b ) recipients were immunized with FVB (H-2 q ) splenocytes, which resulted in reproducible MHC alloimmunization monitored by evaluating anti-MHC alloantibody formation. Consistent with previous results, specific anti-H-2 q alloantibodies were produced that recognized platelets isolated from FVB donors ( Figure 1A) . Importantly, these interactions appeared to be specific to FVB platelets, as serum from FVB-immunized C57BL/6 recipients failed to cross-react with platelets isolated from MHC-identical C57BL/6 donors ( Figure 1B) .
To avoid labeling strategies that may alter platelet clearance in an immune-independent fashion, [15] [16] [17] [18] we crossed C57BL/6 transgenics expressing GFP under a H-2K b promoter 19 with FVB, to generate C57BL/6.GFP 3 FVB progeny (FVB GFP ) that express GFP and H-2 q antigens. To determine whether FVB immunization increased FVB GFP platelet clearance, FVB-immunized C57BL/6 recipients were transfused with FVB GFP platelets and evaluated for platelet clearance at various time points posttransfusion. Transfused platelets could be detected as GFP and CD41-positive events immediately following transfusion ( Figure 1C ; supplemental Figure 1 ). Following transfusion into FVB-immunized C57BL/6 recipients, FVB GFP platelets rapidly declined, within an hour, to ,80% of the initial FVB GFP platelet count detected immediately following transfusion ( Figure 1D ), consistent with rapid antibody-mediated platelet clearance in the clinical setting. 5, 6 Rapid platelet clearance did not appear to reflect an intrinsic defect in the survival of FVB GFP platelets, as this clearance phase failed to occur following transfusion into nonimmunized C57BL/6 recipients ( Figure 1D ). To determine whether platelet clearance required an MHC mismatch, C57BL/6-immunized recipients were transfused with MHC-matched GFP 1 platelets (B6   GFP   ) . Similar to the inability of sera C57BL/6 recipients (n 5 5). Significance was determined in panels A, B, D, and E by Student t test (**P # .01, ****P # .0001). MFI, mean fluorescence intensity; ns, no significance; plts, platelets; SSC, side scatter.
from FVB-immunized C57BL/6 recipients to recognize C57BL/6 platelets ( Figure 1B) , transfusion of B6 GFP platelets into FVB-immunized recipients failed to result in any detectable changes in platelet clearance ( Figure 1E ).
The correlation of anti-MHC alloantibody reactivity and platelet clearance corroborates decades of clinical observations that anti-platelet alloantibodies can mediate platelet clearance. 5, 7 However, as previous studies suggest that some individuals can experience accelerated platelet clearance in the absence of detectable anti-platelet alloantibodies, 2, 3, 20 we next sought to examine potential mechanisms whereby antibody-independent, yet immune-mediated, platelet clearance might occur. As cellular rejection in the setting of transplantation can occur in the absence of anti-MHC alloantibodies, 21 we next sought to determine whether a similar form of cellular immunity might mediate platelet clearance independent of anti-platelet alloantibodies. To examine this, we immunized mMT C57BL/6 (H-2 b ) recipients, which are deficient in B cells and therefore cannot generate antibodies, 22 against FVB. Consistent with the lack of B cells in these mice, immunization failed to result in any detectable anti-FVB alloantibody (Figure 2A-B) . Indeed, no antibodies could be detected in either immunized or nonimmunized recipients ( Figure 2C ). To determine whether FVB-immunized recipients possess the capacity to clear MHC-mismatched platelets, despite the lack of detectable anti-platelet alloantibodies, FVB GFP platelets were transfused into immunized or nonimmunized mMT C57BL/6 recipients. Although no detectable alterations in platelet clearance could be detected 1 hour following transfusion, significant clearance was observed 24 hours following transfusion into FVB-immunized recipients, whereas no alterations in clearance occurred in nonimmunized recipients (Figure 2D -E; supplemental Figure 2) . Importantly, transfusion of MHC-matched B6 GFP platelets into immunized or nonimmunized recipients failed to result in any detectable changes in platelet clearance ( Figure 2D,F) , strongly suggesting that the clearance of FVB GFP platelets reflected an immune-mediated process. These results suggest that although rapid platelet clearance may be antibody-mediated, significant immune-mediated platelet clearance can occur independent of anti-platelet alloantibodies.
Although a variety of cellular factors can mediate immunity independent of antibody function, CD8
1 T cells represent the most classic and well recognized in the setting of transplantation. 21 However, T-cell depletion prior to FVB GFP platelet transfusion (supplemental Figure 3) . Although CD8 1 T-cell depletion significantly attenuated clearance in immunized recipients ( Figure 2G ), injection of an isotype control failed to impact platelet removal (supplemental Figure 3) . Similarly, although previous studies demonstrate that NK cells possess the ability to induce cellular removal, depletion of NK cells failed to significantly alter platelet clearance following transfusion into alloimmunized recipients ( Figure 2G ; supplemental Figures 3-4) . These results suggest that CD8 1 T cells can mediate platelet clearance independent of antibody effector function. When patients fail to respond to platelet transfusion in the absence of detectable anti-platelet alloantibodies, nonimmune causes of platelet clearance become the primary diagnostic and therapeutic focus. 23 However, our results indicate that immune-mediated platelet clearance can occur in the complete absence of detectable anti-platelet alloantibodies through a CD8
1 T-cell-mediated process. The model system used in this study lacks B cells, allowing specific evaluation of CD8 
